Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial

A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study

(2021) Jason Fangusaro et al.   NEURO-ONCOLOGY

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium

(2021) Jack F. Shern et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomes for Kids: The scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing

(2021) Scott Newman et al.   Cancer Discovery

The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets

(2021) Cornelis M. van Tilburg et al.   Cancer Discovery

Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas

(2020) Scott Ryall et al.   CANCER CELL

Selumetinib in Children with Inoperable Plexiform Neurofibromas

(2020) Andrea M. Gross et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015

(2020) Kelly E. Faulk et al.   PLoS One

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

(2020) Keith T. Flaherty et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

(2020) Marie Wong et al.   NATURE MEDICINE

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

(2019) Jason Fangusaro et al.   LANCET ONCOLOGY

Hedgehog signaling inhibitors in solid and hematological cancers

(2019) Jorge E. Cortes et al.   CANCER TREATMENT REVIEWS

Pediatric Trials for Cancer Therapies with Targets Potentially Relevant to Pediatric Cancers

(2019) Thomas J Hwang et al.   JNCI-Journal of the National Cancer Institute

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

(2018) Theodore W Laetsch et al.   LANCET ONCOLOGY

The landscape of genomic alterations across childhood cancers

(2018) Susanne N. Gröbner et al.   NATURE

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours

(2018) Xiaotu Ma et al.   NATURE

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

(2017) Yael P. Mossé et al.   JOURNAL OF CLINICAL ONCOLOGY

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial

(2017) Chih-Jian Lih et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

(2017) Carl E. Allen et al.   JNCI-Journal of the National Cancer Institute

Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

(2017) Carl E. Allen et al.   JNCI-Journal of the National Cancer Institute

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

(2015) Kristian W. Pajtler et al.   CANCER CELL

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers

(2012) Ryan S. Lee et al.   JOURNAL OF CLINICAL INVESTIGATION